Trial Profile
A Randomized, Open Label Intra-patient Dose Escalation Study With an Untreated Reference Group to Evaluate Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Infusions of BPS804 in Adults With Moderate Osteogenesis Imperfecta
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Setrusumab (Primary)
- Indications Osteogenesis imperfecta
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Proof of concept; Therapeutic Use
- Sponsors Novartis; Ultragenyx Pharmaceutical
- 10 Jun 2014 New trial record